Facilitating More OTC Switches In US Graduates To Regulatory Plan On FDA’s Unified Agenda
Fall 2021 Update Also Includes OTC Hearing Aid, Drug Co-Packaging, IND Exemption Timelines
Executive Summary
For first time rules for novel switches and OTC hearings aids are parts of “significant regulatory actions” in agency’s plans. Information is added in Unified Agenda items explaining likely benefits and costs from the changes.
You may also be interested in...
After 10 Years, US FDA ‘Additional Conditions’ Proposed Rule Offers ‘Novel Switch’ Pathway
Publication of "ACNU" proposed rule wasn’t reached in a straight line and featured coining another term with a more of a regulatory sound, “NSURE.” The proposed rule also detours on explaining where the agency wouldn’t steer OTC drug manufacturing and marketing.
After 10 Years, US FDA ‘Additional Conditions’ Proposed Rule Offers ‘Novel Switch’ Pathway
Publication of "ACNU" proposed rule wasn’t reached in straight line and featured coining another term with more of a regulatory sound, “NSURE,” and detours on explaining where the agency wouldn’t steer OTC drug manufacturing and marketing.
House Appropriators Hear Industry’s Self-Care Message, Ring Alarm About Menstrual Products
OTC manufacturers would add endorsements to committee’s discussion of making more consumer health products available in US. In their report, appropriators both introduced a concern and added details to an existing statement about menstrual products.